ArticleRenal failure2025
Plasma levels of the lymphangiogenic factors VEGF-C, VEGF-D, and CXCL-12 are elevated in advanced diabetic nephropathy.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterizing the Immune Cell Infiltration in Renal Interstitium and Therapeutic Targets of Drugs in Diabetic Nephropathy by Multiomics Study.Diabetes & metabolism journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEarly biomarkers for diabetic nephropathy progression remain limited. This study aims to investigate whether plasma levels of VEGF-C, VEGF-D, and CXCL-12 can reflect the severity of diabetic kidney disease (DKD), and to evaluate their potential as biomarkers for disease monitoring.
methodsPatients were divided into normal albuminuria group (UmAlb < 30 mg/24 h,
resultsThe plasma levels of VEGF-C, VEGF-D, and CXCL-12 were significantly increased in all type 2 diabetic kidney disease groups. Correlation analysis revealed that plasma VEGF-C, VEGF-D and CXCL-12 levels were positively correlated with plasma creatinine and urinary microalbumin. Furthermore, these levels were inversely correlated with estimated glomerular filtration rate. In order to distinguish DKD patients in the normal albuminuria group, microalbuminuria group, and macroalbuminuria group, the areas under the receiver operating characteristic curve (AUC-ROCs) of VEGF-C was 0.668 (95%CI: 0.531-0.805), 0.790 (95%CI: 0.678-0.901), and 0.850 (95%CI: 0.756-0.944), respectively. For VEGF-D, the AUC-ROCs were 0.718 (95%CI: 0.587-0.848), 0.873 (95%CI: 0.783-0.963), and 0.931 (95%CI: 0.872-0.991), respectively. Finally, for CXCL-12, the AUC-ROCs were 0.687 (95%CI: 0.554-0.820), 0.816 (95%CI: 0.710-0.921), and 0.903 (95%CI: 0.829-0.977), respectively.
conclusionPlasma VEGF-C, VEGF-D, and CXCL-12 levels is of great value for early diagnosis and assessment of diabetic kidney disease severity. This suggests that these may serve as valuable surrogate markers for clinical outcomes in DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.